PRESS RELEASES

All Releases
Feb 05, 2019
Going Forward, We Will Be Silent Regarding Future Expectations for REMOXY AUSTIN, Texas , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a clinical-stage drug development company, today announced feedback from a meeting held January 31, 2019 with the U.S.
Jan 17, 2019
AUSTIN, Texas , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a drug development company, announced today it has entered into an academic collaboration with UT Austin in support of a product candidate aimed at pain management, abuse and addiction.
Jan 16, 2019
Goal is To Develop a Blood-based Test for Alzheimer’s Disease AUSTIN, Texas , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a clinical-stage drug development company, announced today it has been awarded $1.5 million in research funding from the National Institutes of
Jan 07, 2019
AUSTIN, Texas , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a clinical-stage drug development company, today announced two new publications for its drug candidate, REMOXY ER (extended-release oxycodone). The studies are published in Journal of Opioid Management (Vol 14,
Dec 18, 2018
Filing Will Register Common Stock for Previously Issued Warrants AUSTIN, Texas , Dec. 18, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE) today announced the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC).  This voluntary filing
Dec 06, 2018
AUSTIN, Texas , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, announced today the initiation of a Phase II study to evaluate PTI-125 as a potential first line treatment in patients with Alzheimer’s disease.
Nov 12, 2018
AUSTIN, Texas , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that it has petitioned the Food & Drug Administration ( FDA ) regarding a Complete Response Letter (CRL) for REMOXY issued August 2018.  The FDA and the Company
Oct 29, 2018
- Phase IIa Study Initiation On-track for Q4 2018 - AUSTIN, Texas , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today reported financial results for the third quarter ended September 30 , 2018.  Net loss was $1.3 million , or $0.11 per
Oct 23, 2018
Call to be held on Monday, October 29th at 4:30 p.m. Eastern Time AUSTIN, Texas , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, announced today it will release third quarter 2018 financial results, and hold a conference call with a Q&A
Oct 11, 2018
AUSTIN, Texas , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that Mr. Eric Schoen will join its management team as Chief Financial Officer, effective on or before November 7, 2018 .